Fast Track Designation is a procedural milestone that accelerates FDA interactions but does not predict approval. The Phase 2/3 study (n=12) is tiny and single-arm — efficacy signals are early. The S-3 overhang (~144% dilution) is the dominant near-term factor; monitor for any pricing or exercise of warrants that would crystallize dilution. Approval target of 2028 is distant for a pre-revenue company with going-concern risk.
Price Chart
Executive Summary
Quoin Pharmaceuticals announced FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, the first such designation for this rare disease with no approved therapy. The designation follows July 2026 IND clearance and precedes a planned Phase 2/3 study in 2H 2026. However, the company remains pre-revenue, has a going-concern audit opinion, and filed an S-3 just 4 days ago registering shares representing ~144% of outstanding ADSs, creating massive dilution overhang.
Key Facts
- FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome — first ever for this disease
- QRX003 previously received Fast Track Designation for Netherton Syndrome (March 2026)
- IND for PSS was cleared by FDA in July 2026 — first IND ever submitted for PSS
- Phase 2/3 study expected to initiate in 2H 2026, enrolling up to 12 patients in U.S. and Europe
- Targeting approval of QRX003 for PSS in 2028
- Company filed S-3 on Sept 18, 2026 registering 9,371,895 ADSs for resale — ~144% dilution of outstanding shares
- Company is pre-revenue with a going-concern audit opinion
Financial Impact
No financial data in release; company is pre-revenue. S-3 filed 4 days ago registers shares representing ~144% dilution of outstanding ADSs.
Risk Factors
- Massive dilution overhang from S-3 filed 4 days ago — registered shares represent ~144% of outstanding ADSs
- Pre-revenue with going-concern audit opinion — cash runway limited
- Phase 2/3 study is very small (n=12) and single-arm — efficacy data may not support approval
- Fast Track Designation is procedural and does not guarantee approval or accelerate timeline beyond interactions
- Approval target of 2028 is distant — multiple financing rounds likely needed before then
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366333 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $4.04 | awaiting T+5 | — | $4.09 (+1.11%) |
Oct 19, 2026 8d ago | ANALYST-UPGRADE | $3.98 $4.01 | ▲ +0.75% | ▲ +0.90% | $4.09 (+2.64%) |
Oct 14, 2026 13d ago | 8-K | $4.10 $3.99 | ▼ −2.68% | ▼ −3.14% | $4.09 (−0.37%) |
Oct 12, 2026 15d ago | ANALYST-UPGRADE | $4.36 $3.98 | ▼ −8.72% | ▼ −6.81% | $4.09 (−6.31%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.55 $4.03 | ▲ +11.43% | ▲ +11.15% | $4.09 (+10.22%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.36 | ▼ −4.28% | ▼ −4.70% | $4.09 (−10.32%) |
Sep 28, 2026 29d ago | EFFECT | $5.26 $4.56 | ▲ +13.40% | ▲ +14.61% | $4.09 (+22.34%) |
Sep 22, 2026 5w ago | Press Release | $7.01 $4.88 | ▼ −30.39% | ▼ −29.20% | $4.09 (−41.73%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $5.26 | ▲ +23.77% | ▲ +22.75% | $4.09 (+40.80%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $6.90 | ▲ +2.37% | ▲ +3.33% | $4.09 (−39.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers